Hospital-acquired Clostridium difficile infections significantly prolong hospitalizations independent of patients' baseline risk for death, but the magnitude of the effect may not be as large as some researchers have estimated, according to the authors of a retrospective study from Canada.
Patients with hospital-acquired C difficile infections spent a median of 6 days longer in the hospital than patients without infections, according to an analysis of hospital admissions between July 1, 2002, and Mar. 31, 2009, which controlled for severity of illness. The study, by Alan J. Forster, MD, and colleagues from the Ottawa Hospital Research Institute and University of Ottawa, Ontario, Canada, was published online December 5 in the Canadian Medical Association Journal.
Previous studies estimated that C difficile infections extend hospital stays anywhere from 1 to 3 weeks, the investigators write. However, those studies did not take into account the fact that the longer patients stay in the hospital, the more likely they are to acquire C difficile.
"We found that the impact of hospital-acquired C. difficile on length of stay is more conservative than previous estimates have suggested. Nevertheless, the impact remains large, especially when one considers the aggregated impact. Future studies should incorporate a formal cost analysis and measure patient outcomes from a broader perspective," they conclude.
Read the full article at:http://www.medscape.com/viewarticle/754906?sssdmh=dm1.740456&src=nldne
Source: Medscape Medical News
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More